share_log

Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Stanker James H

SEC announcement ·  Apr 13 04:59
Summary by Futu AI
On January 1, 2024, James H. Stanker, the Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA), completed a stock transaction involving the company's common stock. Stanker acquired 1,675 shares through the exercise or conversion of derivative securities. On the same day, he disposed of 518 shares at a price of $2.79 per share, which was part of a transaction to cover exercise prices or tax liabilities. Following these transactions, Stanker's direct holdings in Processa Pharmaceuticals amounted to 6,120 shares. The total market value of the disposed shares was calculated at $1,445.22.
On January 1, 2024, James H. Stanker, the Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA), completed a stock transaction involving the company's common stock. Stanker acquired 1,675 shares through the exercise or conversion of derivative securities. On the same day, he disposed of 518 shares at a price of $2.79 per share, which was part of a transaction to cover exercise prices or tax liabilities. Following these transactions, Stanker's direct holdings in Processa Pharmaceuticals amounted to 6,120 shares. The total market value of the disposed shares was calculated at $1,445.22.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.